の合成のためのプロトコルオルソ -trifluoromethoxylatedアニリン誘導体

Executive Industry Relevance

This protocol enables the synthesis of ortho-trifluoromethoxylated aniline derivatives, which serve as valuable building blocks for pharmaceutical and agrochemical discovery. The method addresses a key synthetic challenge by providing a scalable, user-friendly route to incorporate the trifluoromethoxy group—a motif known to modulate biological activity and metabolic stability. By enabling access to diverse functionalized derivatives, the approach supports early-stage hypothesis testing and lead optimization in discovery pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Facilitates interrogation of structure-activity relationships by enabling precise incorporation of the trifluoromethoxy group at the ortho position relative to aniline.
• Operational Value: Uses easy-to-handle reagents and standard laboratory equipment, reducing barriers to adoption in medicinal chemistry workflows.
• Predictive Value: Generates compounds with altered electronic and steric properties that can help de-risk target hypotheses through improved binding and selectivity profiles.

Screening & Assay Development

• Scientific Value: Produces structurally diverse, pure compounds suitable for biochemical and cellular assays due to high functional group tolerance.
• Operational Value: Enables gram-scale synthesis, supporting hit-to-lead progression and assay-ready compound supply.
• Assay Readiness: Delivers consistent, reproducible outputs that support structure-activity relationship (SAR) modeling and screening campaign reproducibility.

Translational & Preclinical Research

• Translational Value: Supports continuity from hit identification to preclinical evaluation by providing access to metabolically stable trifluoromethoxylated scaffolds.
• De-risking: Enables exploration of OCF3-mediated effects on bioavailability, brain penetration, and off-target liability in lead optimization.
• Platform Reuse: The method’s broad substrate scope allows adaptation across multiple target classes and chemical series.

Pipeline & Workflow Integration

The method fits within the early discovery continuum, supporting lead generation and optimization through reliable access to trifluoromethoxylated aniline intermediates.

• Discovery Biology: Enables hypothesis-driven synthesis of analogs to probe target engagement and pathway modulation.
• Screening: Delivers quantifiable, pure compounds for dose-response profiling and counter-screening.
• Analytics: Compatible with NMR and HRMS characterization, ensuring data integrity for SAR and ADME assessments.
• Translational Research: Supports progression to preclinical models by generating compounds with improved drug-like properties.
• Enterprise Reuse: Represents a modular, scalable capability applicable across multiple projects and therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Improves predictive confidence in SAR by enabling access to under-explored chemical space.
• Operational Value: Standardized procedure with high reproducibility and scalability to gram quantities.
• Strategic Value: Accelerates lead identification and reduces attrition by improving compound quality early in the pipeline.
• Portfolio Impact: Enhances risk-adjusted decision-making through access to diverse, buildable analogs.

Implementation Considerations

• Requires expertise in air-sensitive techniques and glove box or Schlenk line handling for optimal results.
• Needs access to Togni reagent II, cesium carbonate, and standard organic synthesis instrumentation (rotary evaporator, chromatography systems).
• Demands consistent anaerobic conditions during the trifluoromethoxylation step to ensure reactivity and selectivity.
• Requires thermal stability assessment for nitromethane-based migration step at 120 °C.
• Purification via flash chromatography necessitates solvent systems compatible with polar and non-polar intermediates.

Biopharma FAQs